Skip to content

Sacral Neuromodulation as Treatment for Chronic Constipation

Sacral Neuromodulation as Treatment for Chronic Constipation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03819062
Enrollment
20
Registered
2019-01-28
Start date
2019-09-08
Completion date
2027-02-01
Last updated
2022-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Constipation

Keywords

Constipation, spinal cord injury, back pain, High-Resolution Colonic Manometry, Anorectal Manometry

Brief summary

The objective of this study is to study if low level laser therapy will do more good than harm for patients with severe chronic refractory constipation. It is a proof of concept study without a placebo arm.

Detailed description

Patients will be offered the therapy if High-Resolution Colonic Manometry has shown that coordination between colon motility and recto-anal activity is abnormal and that autonomic nervous system assessment suggests a dysfunction of communication between the spinal cord autonomic nerves and the colon-rectum-anus. The therapy consists of a 3 week treatment with a total of 8 sessions of low level laser therapy. Effects will be assessed using symptom and quality of life questionnaires and physiological assessments of colon and pelvic floor function, at 4 weeks and 12 weeks.

Interventions

DEVICELow Level Laser Therapy

A 3 week treatment period with 8 treatment sessions in total.

Sponsors

McMaster University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

proof of concept

Eligibility

Sex/Gender
ALL
Age
6 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with severe chronic refractory constipation * Must have undergone high resolution colonic manometry that shows abnormal coordination between colonic motility and ano-rectal function.

Exclusion criteria

* Pregnant patients * Known malignancies in the area of treatment * Active bleeding in area of treatment * Active deep vein thrombosis * When tatoos are present at area of treatment * Patients that are light sensitive * Patients who take NSAIDS or steroids.

Design outcomes

Primary

MeasureTime frameDescription
Change in number of bowel movements/week12 weeks(significance level P\<0.05 comparing before and after).

Secondary

MeasureTime frameDescription
Change in symptoms using the questionnaire PAC-SYM4 weeksThe PAC-SYM questionnaire is a 12-item questionnaire that evaluates the severity of symptoms of constipation in 3 domains (stool, rectal, and abdominal symptoms) on a 5-point Likert scale ranging from 0 (absent) to 4 (very severe). Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items (ie, symptoms). The range of the domain or total score is 0 (response is 'absent' for each item) to 4 (response is 'very severe' for each item). A negative change from baseline indicates improvement, a positive change indicates worsening of symptoms. The minimum important difference indicating clinically significant improvement is minus 0.6 (Saito & Camilleri, 2018)
Change in quality of life assessed by questionnaire PAC-QOL4 weeksThe PAC-QOL scale is a 28-item self-report instrument designed to evaluate the burden of constipation on patients' everyday functioning and well-being. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). The instrument can be used to generate an overall score, but is also reported to assess 4 specific constipation-related domains including: 1) Worries and concerns (11 items), 2) Physical discomfort (4 items), 3) Psychosocial discomfort (8 items), and 4) Satisfaction (5 items). Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items. The range of the domain or total score is 0 (response is 'not at all' for each item) to 4 (response is 'extremely' for each item). A negative change from baseline indicates improvement, a positive change indicates worsening of symptoms. The minimum difference indicating clinically significant improvement is -0.5 (Marquis et al., 2005)
Autonomic function assessment4 weeksIncrease or decrease in parasympathetic reactivity in response to a change in body position from supine to standing expressed as Respiratory Sinus Arrhythmia (ln(ms2)); comparison before and after treatment
Anal spincter pressure4 weeksAnorectal manometry, measuring resting anal sphincter pressure in mmHg; comparison before and after treatment.
Change in anal sphincter pressure due to attempting defecation4 weeksAnorectal manometry, measuring change in resting anal sphincter pressure in mmHg; comparison before and after treatment

Countries

Canada

Contacts

Primary ContactJihong Chen, MD PhD
chen338@mcmaster.ca2263439909
Backup ContactJan D Huizinga, PhD
huizinga@mcmaster.ca2263438888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026